




FIG. 1




FIG. 2

EFFECT OF COMPOUNDS ON LNCaP-AR




FIG. 3




FIG. 4




FIG. 5




FIG. 6

7/29




FIG. 7A




FIG. 7B




FIG. 8

9/29




FIG. 9A




FIG. 9B

10/29




FIG. 10

11/29




FIG. 11

12/29




FIG. 12A




FIG. 12C




FIG. 12B




FIG. 12D




FIG. 13

14/29




FIG. 14

CHARACTERISTICS OF Bicalutamide, RD37, RD131 AND RD162





NAME	STRUCTURE	IC ₅₀ [nM]	LogP	C _{SS} ,10mpk [μM]	C _{SS} ,25mpk [μM]	C _{SS} ,50mpk [μM]
Bic.		1000	2.91	10.0	11.4	11.9
RD37		124	4.20	NA	NA	NA
RD131		92	3.44	0.39	0.43	0.40
RD162		122	3.20	9.9	10.7	10.2

FIG. 15A




FIG. 15B




FIG. 16




FIG. 17




FIG. 18




FIG. 19A

FIG. 19B




FIG. 19C




FIG. 20A




FIG. 20B




FIG. 20C

21/29




FIG. 21A




FIG. 21B




FIG. 22




FIG. 23A




FIG. 23B




FIG. 24




FIG. 25




FIG. 26




FIG. 27




FIG. 28




FIG. 29